Kunst was ousted from the Seattle-based Aurion after Swiss eye-care giant Alcon acquired a majority interest in the company ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company ...

Alcon’s CEO, David Endicott ... Aurion launched Vyznova™, its first commercial cell therapy product in Japan, for the treatment of bullous keratopathy, a condition that seriously threatens ...

Alcon (SIX/NYSE: ALC), the global leader in eye ... Vyznova™ (which includes neltependocel), in Japan for the treatment of bullous keratopathy of the cornea. Bullous keratopathy is a sight ...

Spectacle lenses dominate Japan's myopia control market through cultural trust and accessibility, while multifocal and soft contact lenses gain tract ...

In September 2024, Aurion launched Vyznova™, its first commercial cell therapy product in Japan, for the treatment of bullous keratopathy, a condition that seriously threatens vision. This strategic ...

The global implantable collamer lens market is set to experience remarkable expansion in the coming decade, driven by the increasing adoption of minimally invasive vision correction procedures. Market ...

Futures tied to Canada's main stock index rose on Tuesday, as geopolitical tensions and tariff uncertainties lifted the prices of oil, gold and copper. The TSX Composite Index recovered 335.62 points, ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...